| Name | Title | Contact Details |
|---|
UCM Digital Health (UCM) delivers an end-to-end digital first healthcare solution that combines a digital front door platform with a 24/7 emergency medicine treat, triage and navigation telehealth service – designed to lower costs, improve outcomes and provide a better patient experience. UCM Digital Health brings together clinical expertise, advanced technology and compassionate care to offer powerful advantages for insurers, brokers, employers, patients and providers. UCM Digital Health partners with insurers, employers, patients, providers, technology solutions companies – covering every corner of the healthcare ecosystem to deliver a complete, trusted, technology-based and data-driven healthcare solution. UCM Digital Health`s unique combination of digital front door platform plus emergency medicine triage and navigation expertise allows all care to begin digitally in one place. Located in Troy, New York, UCM Digital Health was founded in 2015 by emergency clinicians Keith Algozzine, PA-C and Michael Bibighaus, M.D., in an effort to combine healthcare and technology who continue to run the operations of the company.
S&S Drug is a Beloit, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Right Trend is a Bellerose, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
WIL Research Company, Inc. is a privately held global Contract Research Organization that provides product safety toxicological research, bioanalytical, and formulation services to the pharmaceutical, biotechnology, chemical, agrochemical, and food products industries as well as manufacturing support for clinical trials.
AVEO Oncology (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering and developing targeted therapies designed to provide substantial impact in patients` lives with clear unmet medical needs. AVEO`s proprietary Human Response PlatformTM provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics.